Industry

DUBLIN–(BUSINESS WIRE)–The “US Neuropathic Pain Market and Competitive Landscape – 2022” report has been added to ResearchAndMarkets.com’s offering. The latest research US Neuropathic Pain Market and Competitive Landscape Highlights – 2022, provides comprehensive insights into Neuropathic Pain pipeline products, Neuropathic Pain epidemiology, Neuropathic Pain market valuations and forecast, Neuropathic Pain drugs sales and competitive landscape … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report by Drug, by Service, by Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Pancreatic), by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The global cancer immunotherapy drug discovery outsourcing market size is expected to reach USD … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Sterilization Equipment Market Size, Share & Trends Analysis Report by Product (Heat Sterilizers, Low-temperature Sterilizers, Sterile Membrane Filters, and Radiation Sterilization Devices), by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The global sterilization equipment market is expected to reach USD 15.6 billion by 2030, registering a CAGR of … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “North America Healthcare Consulting Services Market By End User, By Type of Service, By Country, Opportunity Analysis and Industry Forecast, 2021-2027” report has been added to ResearchAndMarkets.com’s offering. The North America Healthcare Consulting Services Market is expected to witness market growth of 11.1% CAGR during the forecast period (2021-2027). The healthcare consulting services … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Anti-snoring Devices and Snoring Surgery Market Size, Share & Trends Analysis Report by Type (Oral Appliances/Mouthpieces, Position Control Devices), by Region (APAC, EU, North America), and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The global anti-snoring devices and snoring surgery market size is expected to reach USD 2.65 billion … [Read more…]

Official podcast of the inventors of online substance use disorder (SUD) treatment offers listeners an incredible lineup of acclaimed experts and inspirational individuals REDWOOD CITY, Calif.–(BUSINESS WIRE)–Lionrock, the inventor of online treatment and recovery services for substance use disorders (SUDs) in the United States, is taking the lead during National Recovery Month with a high … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Nasal Drug Delivery Mode Market, by Therapeutic Application, by Dosage Form, by Container Type, by System Type, by End-users, by Distribution, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028” report has been added to ResearchAndMarkets.com’s offering. Drug delivery refers to the technology utilized to present the drug to … [Read more…]

Influenza vaccine candidate OVX836 safety profile and efficacy signals from Phase 2a dose-optimization study to be presented at UIV 2022 Preclinical proof of cross-protection against SARS-COV-2 with OVX033 in hamster challenge model to be presented at Options XI Additional results on the synergy of co-administering T-cell based vaccine candidate OVX836 with traditional antibody-based flu vaccines … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “eClinical Solutions Market Size, Share & Trends Analysis Report by Product (eCOA, CTMS, EDC & CDMS), by Delivery Mode (Web-hosted, Licensed Enterprise, Cloud-based), by Development Phase, by End Use, by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The global eClinical solutions market size is expected to reach USD … [Read more…]

LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety … [Read more…]